The following publications provide more information about SAJE’s technology:

  1. This paper details some of the key data that forms the basis of the first approved patent relating to GSNOR inhibition that SAJE has licensed from Indiana University: Sanghani, P. C., Davis, W. I., Fears, S. L., Green, S. L., Zhai, L., Tang, Y., Martin, E., Bryan, N. S., and Sanghani, S. P. (2009) Kinetic and cellular characterization of novel inhibitors of S-nitrosoglutathione reductase, J Biol Chem 284, 24354-24362. Published online 2009 Jul 11. doi: 10.1074/jbc.M109.019919
  2. This work was a collaboration between SAJE and the Roberts/Jaffar lab at the University of Montana: Ferrini, M. E., Simons, B. J., Bassett, D. J., Bradley, M. O., Roberts, K., and Jaffar, Z. (2013) S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity, PLoS One. 2013 Jul 25;8(7):e70351. doi: 10.1371/journal.pone.0070351. Print 2013.
  3. This work is a collaboration between SAJE and the Atamas/Luzina lab at the University of Maryland School of Medicine, using SPL-334 in a gold-standard model of IPF. Pharmacological in vivo inhibition of S-nitrosoglutathione reductase attenuates bleomycin-induced inflammation and fibrosis. Irina G. Luzina, Virginia Lockatell, Nevins W. Todd, Pavel Kopach, Helen Pentikis, Sergei P. Atamas. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201 (I.G.L., V.L., N.W.T., P.K., S.P.A); SAJE Pharma, Baltimore, MD 21218 (H.P.). JPET Fast Forward. Published on July 24, 2015 as DOI: 10.1124/jpet.115.224675
  4. This abstract was published by scientists at Duke University, with whom we have a collaboration. GSNORi in their abstract is the same compound as SPL-334: Systemic And/Or Local Aerosol Inhibition Of S-Nitrosoglutathione Reductase (GSNOR) Ameliorates Physiologic, Biologic, And Proteomic Phenotypes In An Allergic Mouse Model Of Inflammatory Airway Disease. Loretta G. Que, Matthew W. Foster, Erin N. Potts, Erik J. Soderblom, Zhonghui Yang, David M. Gooden, M. A. Moseley, and W M. Foster. Chapter DOI: 10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A407510.
  5. This paper was also done by the Duke scientists and shows that SPL-334 (referred to as GSNORi in their paper) induces Nrf2: Foster, M. W., Yang, Z., Gooden, D. M., Thompson, J. W., Ball, C. H., Turner, M. E., Hou, Y., Pi, J., Moseley, M. A., and Que, L. G. (2012) Proteomic characterization of the cellular response to nitrosative stress mediated by s-nitrosoglutathione reductase inhibition, J Proteome Res 11, 2480-2491.
  6. This abstract was published by scientists at GSK and corroborates the work by Duke showing that SPL-334 (referred to as GSNORi in the GSK abstract) induces Nrf2. Inhibition of S-Nitroso Glutathione Reductase (GSNOR) Up-Regulates The Nrf2 Pathway In Human Bronchial Epithelial Cells. Diana G. Chalupowicz and Yolanda Sanchez Lopez-Boado.
  7. A Novel Therapeutic Target in Asthma: Translational Evidence for Inhibition of S-Nitrosoglutathione Reductase (GSNOR). Que, L.G., et al. American Thoracic Society, 2015.